---
figid: PMC9525275__41401_2021_852_Fig2_HTML
pmcid: PMC9525275
image_filename: 41401_2021_852_Fig2_HTML.jpg
figure_link: /pmc/articles/PMC9525275/figure/Fig2/
number: Fig. 2
figure_title: Targeting the HIF-2α signaling pathway
caption: Under normoxia, HIF-2α protein is hydroxylated and degraded to maintain a
  low level. Under hypoxia, HIF-2α accumulates and dimerizes with ARNT to active target
  gene expression. PHD inhibitors block HIF-2α degradation and activate the HIF-2α
  signaling pathway. The binding of an antagonist disrupts HIF-2α/ARNT interaction
  and blocks the HIF-2α signaling pathway. The binding of an agonist enhances HIF-2α/ARNT
  interaction and activates target gene expression.
article_title: Current strategies and progress for targeting the “undruggable” transcription
  factors.
citation: Jing-jing Zhuang, et al. Acta Pharmacol Sin. 2022 Oct;43(10):2474-2481.
year: '2022'

doi: 10.1038/s41401-021-00852-9
journal_title: Acta Pharmacologica Sinica
journal_nlm_ta: Acta Pharmacol Sin
publisher_name: Springer Nature Singapore

keywords:
- transcription factor
- drug discovery
- undruggable
- PROTAC
- protein-protein interaction
- post-translational modification

---
